Sharinky, I agree that Vascepa should be considered an essential medication but it probably won’t be until a generic form is available just like statins. I hope I’m wrong but I believe that is why statins are virtually free for all to take without impact against prescription benefit totals, copays or deductibles involved. It’s based on cost vs benefit so maybe with Vascepa’s low price/benefit ratio, concessions can be made. Vascepa should be given a vary favorable tiering as a preferred brand name medication once it receives an expanded use label from the FDA. I agree that it may take some time for formularies to make an official change in tiering( reviewed and changed monthly and quarterly) but it shouldn’t stop successful appeals for lower tiering and copays for those that qualify for Vascepa under the new broader label. Additionally, Amarin does have lobbyist and I hope all those 3 letter organizations go to bat for Vascepa’s wide spread use and affordability to users( Medicare and high copay plans). The whole system is set up to keep people from getting brand name medications but Vascepa is unique in that it doesn’t have a generic or bio similar available substitute so when a prescription is written it should get filled under the preferred brand tier and copay. Many formulary tiering and copay changes are coming with the expanded label. All IMO and as I understand it.
News 
Market Data 
Discover 
